Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Stellantis Full Year 2025 Earnings Call - Decisive Reset Returned H2 Growth; 2026 Is Year of Execution
Stellantis framed 2025 as a year of reset and paid the near-term cost. The company returned to top-line growth in H2 2025 after product and commercial fixes, but the income statement still shows the d...
- Company view: 2025 was a deliberate reset year, H2 showed return to top-line growth and early benefits from actions taken.
- Full-year results: consolidated shipments 5.5 million units (+1%), net revenues EUR 153 billion (-2%), AOI margin negative 0.5%, industrial free cash flow outflow EUR 4.5 billion.
- H2 improvement: H2 net revenues growth and pricing gains (net pricing +2% in H2 North America) helped drive a sequential recovery; H2 industrial FCF was negative EUR 1.5 billion, a 50% sequential improvement and 73% YoY improvement.
- +15 more takeaways
Cronos Group Q4 2025 Earnings Call - Record 2025, Spinach vape breakout and Netherlands acquisition
Cronos closed 2025 with its strongest year yet, reporting record net revenue, gross profit, and Adjusted EBITDA while growing organically by 25%. The fourth quarter accelerated that momentum, with con...
- Cronos reported a record 2025, growing net revenue organically by 25% year-over-year and posting record full-year gross profit and Adjusted EBITDA.
- Q4 2025 consolidated net revenue was $44.5 million, up 47% year-over-year, driven by higher flower sales in Israel and Canada and stronger Canadian extract sales.
- Spinach was the company standout in Canada, becoming the number 2 overall vape brand in December and the number 1 vape cartridge brand in Q4, led by Cherry Crush and Blueberry Dynamite.
- +11 more takeaways
Dorman Products Fourth Quarter 2025 Earnings Call - Tariff timing to pressure early 2026 margins, but company guides 7%-9% sales growth
Dorman reported a solid 2025 on the top line and margins, but the call read like a company still wrestling with trade policy aftershocks. Full-year sales hit $2.13 billion, up 6%, and adjusted EPS ros...
- 2025 full-year net sales $2.13 billion, up 6% year-over-year; Q4 net sales $538 million, up about 1% versus prior year.
- Adjusted diluted EPS for 2025 was $8.87, a 24% increase year-over-year; Q4 adjusted diluted EPS was $2.17, down 1% versus a very strong Q4 2024.
- Tariffs remain the dominant narrative. Management estimates incremental tariffs reduced 2025 adjusted EPS by approximately $1.25.
- +14 more takeaways
PENN Entertainment Q4 2025 Earnings Call - Rebrand and iCasino Momentum Set Interactive to Break Even in 2026
PENN used Q4 to show that the heavy strategic investments of the last few years are starting to pay off. The U.S. sportsbook rebrand to theScore Bet on December 1 delivered retention and a December po...
- Retail: Q4 retail revenues were $1.4 billion, with retail adjusted EBITDAR of $456.4 million and segment adjusted EBITDAR margin of 32.3%.
- Interactive: Q4 interactive revenues were $398.7 million, including a tax gross up of $182.7 million, and the interactive segment posted an adjusted EBITDA loss of $39.9 million for the quarter.
- Rebrand: PENN rebranded its U.S. sportsbook to theScore Bet on December 1, retaining users through the transition and delivering positive adjusted EBITDA in December.
- +14 more takeaways
Qnity Electronics Q4 2025 Earnings Call - Sustained momentum with conservative 2026 guide, $100M transformation to capture AI-led semiconductor demand
Qnity closed 2025 with steady execution: Q4 net sales of $1.2 billion (up 8% y/y) and full-year net sales of $4.75 billion, delivering 10% organic sales growth and $1.4 billion of adjusted pro forma o...
- Q4 net sales $1.2B, +8% year-over-year; full-year 2025 net sales $4.75B, +10% organic growth.
- Adjusted pro forma operating EBITDA for FY2025 was $1.4B, margin 29.5%; Q4 adjusted pro forma operating EBITDA was $349M and adjusted pro forma EPS was $0.82.
- Segment performance split: Semiconductor Technologies $2.65B in sales, organic growth 8%; Interconnect Solutions $2.1B, organic growth 12% with strong operating leverage.
- +12 more takeaways
Rackspace Technology Q4 2025 Earnings Call - Pivot to Platform Engineering as Backbone for Enterprise AI
Rackspace closed Q4 2025 with revenue of $683 million, beating guidance as public cloud outperformed while private cloud underdelivered due to a slow-ramping large healthcare deployment. Management fr...
- CEO Gajen Kandiah, five months into the role, says the company is pivoting to a platform engineering model, embedding engineers inside customer environments to operationalize AI, not just advise or resell infrastructure.
- Rackspace positions itself as the infrastructure and operations backbone for enterprise AI, with private cloud and governed environments central for data-sensitive and regulated workloads.
- Q4 GAAP revenue was $683 million, with private cloud at $241 million (below guidance) and public cloud at $442 million (above guidance).
- +13 more takeaways
Park Dental Partners Q4 2025 Earnings Call - IPO Completed, Specialty Growth and Land-and-Expand M&A Take Center Stage
Park Dental Partners closed 2025 with record revenue and adjusted EBITDA, an early-December IPO, and a clear land-and-expand playbook aimed at growing the number of doctors across its footprint. Q4 re...
- Q4 2025 revenue $61.2 million, up 7.5% year-over-year; full-year 2025 revenue $244.5 million, up 6.4%.
- Same-practice revenue growth was 6.3% in Q4 and 5.8% for full-year 2025; normalizing for one fewer operating day, full-year same-practice growth would be 6.9%.
- Multi-specialty and specialty services are outpacing general dentistry, with specialty practice revenue up 11.0% for the year to $65.5 million, and Q4 multi-specialty revenue up 11.3% to $16.5 million.
- +11 more takeaways
Eni Q4 2025 Earnings Call - Execution Delivers Sector-leading Upstream Growth and Strong Cash Generation
Eni spent 2025 proving its playbook works. Operational execution—six project start-ups, four FIDs and high-value discoveries—pushed full-year production to 1.728 million bpd, beat guidance, and drove ...
- 2025 operational execution outperformed plan: six major project start-ups and four FIDs, supporting underlying production growth of ~4% and a 2020-2025 cumulative growth above 7%.
- Full-year production reached 1.728 million barrels per day, 2% above guidance; Q4 production was 1.839 million bpd, +7% year-on-year and +5% sequentially.
- Discovery run remained strong: ~900 million barrels of new resources in 2025; over 10 billion barrels discovered since 2014 at under USD 1 per barrel; 70% of discoveries are gas, 30% oil.
- +17 more takeaways
Zai Lab Q4 2025 Earnings Call - Zoci races to pivotal readouts with intracranial activity and a 2028 approval target
Zai Lab closed 2025 with steady commercial momentum in China, $127.6 million in Q4 revenue and $460.2 million for the year, a cash balance of $790 million, and improving operating leverage. Management...
- Q4 2025 revenue was $127.6 million, up 17% year over year; full-year 2025 revenue was $460.2 million, up 15% year over year.
- Zai Lab ended the quarter with $790 million in cash and reported improved operating leverage, with R&D and SG&A down as a percentage of revenue.
- Loss from operations improved 19% year over year to $229.4 million, and improved 25% on an adjusted basis excluding non-cash items.
- +13 more takeaways
Akebia Therapeutics Q4 2025 Earnings Call - Vafseo launch gains traction despite second-half hiccups, data will decide pace of uptake
Akebia closed 2025 on a pivot point. The commercial introduction of Vafseo propelled product revenue growth, but the launch stalled in the back half of the year as adherence and a USRC inventory reshu...
- Vafseo launched in 2025 and materially contributed to growth, with Vafseo net product revenue of $45.8 million in calendar 2025 and $6.2 million in Q4 2025.
- Combined product revenue from Vafseo and Auryxia was $227 million in 2025, while total company revenues were $236.2 million for the year, up from $160.2 million in 2024.
- Demand for Vafseo flattened in H2 2025, with reported demand around $12 million in Q2, $12 million in Q3 and $11 million in Q4, a pattern management attributes to operational and adherence issues rather than lack of interest.
- +13 more takeaways